Compass Therapeutics, Inc. (CMPX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Compass Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 1.89 at 3:45 pm ET, low 1.83 at 12:00 pm ET.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
the bull case· 3
7
disclosed supplier and customer ties in SEC filings
sec filingsedgar216
managers reporting a position in thirteen F filings
13fJun 30 '26+14.17%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 3
7 of 7
recent reports where the move came in under the options implied range
earnings historyimplied vs realized5 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2620
managers whose positions together make up four fifths of reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Mar 22 '27 report. Not a forecast, not advice.
Of the 6 companies Compass Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
215 managers report a position worth $363.7M between them, and 20 of them hold 80% of it.
tall tick = annual report · 2 on record
CMPX (Compass Therapeutics, Inc.) has 6 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.